Bluefin Capital Management LLC Acquires New Holdings in Inhibrx Biosciences, Inc. $INBX

Key Points

• Bluefin Capital Management LLC has acquired a new stake in Inhibrx Biosciences, totaling 11,408 shares valued at approximately $160,000 during the first quarter.
• A number of large investors, including Bank of America and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., have also purchased new stakes, increasing institutional ownership to 82.46%.
• Inhibrx Biosciences reported an earnings per share of ($1.85), surpassing analysts' estimates, while the stock holds a consensus rating of "Hold" from equities research analysts.

Bluefin Capital Management LLC bought a new stake in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,408 shares of the company's stock, valued at approximately $160,000. Bluefin Capital Management LLC owned 0.08% of Inhibrx Biosciences as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its holdings in shares of Inhibrx Biosciences by 2.6% in the 1st quarter. Bank of New York Mellon Corp now owns 52,800 shares of the company's stock worth $739,000 after purchasing an additional 1,355 shares during the period. State of Wyoming acquired a new position in Inhibrx Biosciences during the fourth quarter valued at approximately $83,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Inhibrx Biosciences during the fourth quarter worth approximately $102,000. GAMMA Investing LLC raised its stake in shares of Inhibrx Biosciences by 9,834.8% in the 1st quarter. GAMMA Investing LLC now owns 6,855 shares of the company's stock valued at $960,000 after acquiring an additional 6,786 shares during the period. Finally, BNP Paribas Financial Markets purchased a new stake in Inhibrx Biosciences during the 4th quarter worth $128,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on INBX shares. JMP Securities reiterated a "market perform" rating on shares of Inhibrx Biosciences in a report on Friday, August 22nd. Wall Street Zen raised shares of Inhibrx Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Inhibrx Biosciences presently has an average rating of "Hold".

Inhibrx Biosciences Price Performance

INBX traded down $0.18 during trading on Monday, hitting $27.34. 45,612 shares of the stock traded hands, compared to its average volume of 105,917. The business has a 50 day moving average price of $24.12 and a 200 day moving average price of $17.07. The company has a debt-to-equity ratio of 1.45, a current ratio of 4.98 and a quick ratio of 4.98. Inhibrx Biosciences, Inc. has a twelve month low of $10.81 and a twelve month high of $30.23. The company has a market cap of $395.88 million, a price-to-earnings ratio of -2.58 and a beta of 0.31.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($1.85) earnings per share for the quarter, beating the consensus estimate of ($2.92) by $1.07. The business had revenue of $1.30 million during the quarter. Equities research analysts forecast that Inhibrx Biosciences, Inc. will post 104.88 earnings per share for the current fiscal year.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.